

Original Research Article

Antinociceptive Properties and Acute Toxicity of Ethanol Extract of *Bromelia laciniosa* Mart. ex Schult. f. (Bromeliaceae)

Sarah RG de Lima-Saraiva¹, Henrique CC Saraiva², Juliane C Silva², Leonardo F Neves², Patrícia KF Damasceno³, Carla RC Branco³, Alexsandro Branco³, Elba LC Amorim¹ and Jackson RGS Almeida²

¹Universidade Federal de Pernambuco, 50.740-521, Recife, Pernambuco, ²Universidade Federal do Vale do São Francisco, 56.304-205, Petrolina, Pernambuco, ³Universidade Estadual de Feira de Santana, 44.036-900, Feira de Santana, Bahia, Brazil

*For correspondence: **Email:** jackson.guedes@univasf.edu.br; **Tel/Fax:** + 55-87-21016862

Received: 9 September 2013

Revised accepted: 24 August 2014

Abstract

Purpose: To investigate the antinociceptive activity and acute toxicity of the ethanol extract of *Bromelia laciniosa* leaf.

Methods: A high performance liquid chromatography HPLC fingerprint of phenolic compounds was developed. The antinociceptive effect of ethanol extract (BI-EtOH) in mice was carried out using chemical (writhing and formalin) and thermal (hot plate) models of nociception. The acute toxicity of the extract was performed in mice using doses of 2.0 g/kg intraperitoneally and 5.0 g/kg orally. Blood was removed for laboratory analysis of hematological and biochemical parameters.

Results: BI-EtOH (100, 200 and 400 mg/kg, i.p.) reduced the number of writhing (91.80, 93.44 and 78.68 %, respectively) and the number of paw licks during the first (60.86, 62.84 and 66.79 %) and second phase (91.93, 82.18 and 88.73 %) of the formalin test. Naloxone (1.5 mg/kg, i.p.) antagonized the antinociceptive action of BI-EtOH (100 mg/kg), and this finding suggests involvement of opioid mechanism. The effect of BI-EtOH on hot plate response provides a confirmation of its central effect.

Conclusion: *B. laciniosa* leaf extract has antinociceptive properties. Peripheral, and at least in part, central mechanisms, may be involved in this antinociceptive effect. The ethanol leaf extract apparently presents no significant toxicity.

Keywords: *Bromelia laciniosa*, Nociception, Pain, Writhing, Acute toxicity

Tropical Journal of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals (DOAJ), African Journal Online, Bioline International, Open-J-Gate and Pharmacy Abstracts

INTRODUCTION

The Bromeliaceae, one of the largest botanical families of the New World, is distributed extensively in tropical America [1]. This family comprises 58 genera and 3172 species [2]. Considering the large number of species of the Bromeliaceae family, few have been studied chemically so far. Despite this, there is a considerable amount of identified compounds,

which mostly belong to the class of triterpenoids and flavonoids. Other classes of compounds such as sterols, diterpenes, cinnamic acids, lignans, nitrogen compounds, amongst others, were also identified [3]. Some studies have demonstrated that species of the Bromeliaceae family have pharmacological properties such as antioedematogenic and free radical scavenging [4], antinociceptive and anti-inflammatory [5],

anti-allergic [6], antiulcer [7], cytotoxic [8], antioxidant and antimycobacterial activities [9].

Bromelia is one of the most diverse genera within Bromeliaceae and includes 56 species [2]. Some species of this genus are used in traditional medicine as a vermifuge, anti-helminthic, diuretic, in cases of respiratory and kidney problems, intestinal disorders, diabetes, amongst others [10]. *Bromelia antiacantha* is one of the most studied species [11]. *Bromelia laciniosa* is a species native to the Brazilian Caatinga which is known in the Northeast region of Brazil as "macambira" and is used in the alimentation of man and domestic animals, especially in times of drought [12]. From the base of the leaves is extracted a mass, that produces a type of bread [13]. The main therapeutic indications are for treating child colic, diarrhea, fever, jaundice, dandruff and hepatitis [14]. The decoction of the roots is also popularly used against hepatitis and intestinal disorders, as a diuretic, while the dried and powdered leaves are used in cooking as a source of protein [3,10].

Considering the popular use and because of the scarcity of pharmacological studies about this species, this study evaluated the antinociceptive activity as well as the acute toxicity of the ethanolic extract from leaves of *Bromelia laciniosa* in mice.

EXPERIMENTAL

Plant material

The leaves of *Bromelia laciniosa* Mart. ex Schult. f. were collected in the city of Petrolina, State of Pernambuco, Brazil, in January of 2011 (Coordinates 08°59'16.90" S and 40°35'20.60" W). A voucher specimen (no. 6442) was deposited at the Herbarium Vale do São Francisco (HVSF) of the Universidade Federal do Vale do São Francisco.

Preparation of extracts

The leaves of *B. laciniosa* dried and pulverized (879 g) were subjected to maceration with 95 % EtOH for 72 h. The solution was filtered and concentrated in a rotatory evaporator oven at 50 °C, producing 39 g of crude ethanol extract (BI-EtOH).

Analysis of BI-EtOH by high performance liquid chromatography (HPLC)

The solvents used in high performance liquid chromatography are of analytical grade from Merck®. A Milli-Q System® (Bedford, MA, USA)

was used to purify the water. Analysis using high performance liquid chromatography was performed on a Merck-Hitachi liquid chromatograph LaChrom Elite® equipped with a VRW HITACHI L-2130 pump, a VRW HITACHI L-2300 Diode-Array Detector (DAD), and an auto sampler with a 100 µl loop. The data was acquired and processed using Ezchrom Elite software. The extract was analyzed using a reverse-phase HPLC column: Purospher® STAR RP-18e (250 mm × 4.6 mm i.d., 5 µm) column (Merck). The mobile phase was composed of solvent (A) H₂O/H₃PO₄ 0.1 % and solvent (B) MeOH. The solvent gradient was composed of A (75 - 0 %) and B (25 - 100 %) for 20 min, then 100 % B for 4 min, then again at the initial conditions (75 % A and 25 % B) for 10 min. A flow rate of 1.0 ml/min was used in a 30 °C oven, and 20 µl of each sample was injected. The procedure was repeated three times for each sample. Samples and mobile phases were filtered through a 0.22 µm Millipore filter prior to HPLC injection. Spectra data were recorded from 200 to 400 nm during the entire run.

Animals

Male and female adult albino Swiss mice (25 - 35 g) were used throughout this study. The animals were randomly housed in appropriate cages at 22 ± 2 °C on a 12 h light/dark cycle (lights on at 6:00 a.m.) with free access to food and water. When necessary, animals were deprived of food 12 h prior to the experiments. Experimental protocols and procedures were approved by the Federal University of Vale do São Francisco Animal Care and Use Committee by number 21051023.

Acetic acid-induced writhing test in mice

This test was performed as described by Koster et al [15]. Mice (n = 6) were intraperitoneally pre-treated 30 min before the nociceptive agent, acetic acid 0.9 % (v/v, 10 ml/kg). Vehicle (saline), BI-EtOH (100, 200 and 400 mg/kg, body weight), acetylsalicylic acid (ASA, 200 mg/kg) and morphine (10 mg/kg) were administered before acetic acid injection. Following the injection of acetic acid, the intensity of nociceptive behavior was quantified by counting the total number of writhes (a response consisting of contraction of the abdominal wall, pelvic rotation followed by hind limb extension) occurring between 5 and 15 min after stimulus injection [16].

Formalin test

Twenty microlitres of 2.5 % formalin was injected subcutaneously into the right hind paw of mice.

The time (in seconds) spent in licking and biting responses of the injected paw was taken as an indicator of pain response. Responses were measured for 5 min after formalin injection (first phase, neurogenic phase) and 15-30 min after formalin injection (second phase, inflammatory phase). BI-EtOH (100, 200 and 400 mg/kg), ASA (200 mg/kg) and morphine (10 mg/kg) were administered intraperitoneally 60 min before formalin injection. Control animals received the same volume of saline. Mice were observed in the chambers with a mirror mounted on three sides to allow view of the paws [17].

Hot plate test

Mice were pre-selected on the hot plate at 55 ± 0.5 °C. Licks on the rear paws were the parameters of observation. Animals showing a reaction time (latency for licking the hind feet or jumping) greater than 20 s were discarded. The animals were then treated with vehicle (saline, 0.1 ml/10 g), morphine (10 mg/kg) and BI-EtOH (100, 200 and 400 mg/kg) intraperitoneally. Latency time (in seconds) for each mouse was determined on the hot plate during the maximum period of 20 s, at intervals of 30, 60, 90 and 120 min after the administration of the extract [18].

Acute toxicity

Animals were randomly divided in groups of five male and five female Swiss mice (n=10). Animals were administered 2.0 g/kg intraperitoneally and 5.0 g/kg orally of the crude ethanol extract of *Bromelia laciniosa*. Control group received vehicle. Subsequently, the animals were observed for 14 days to evaluate the presence of signs of toxicity. Mortality in each group within 72 h was recorded. LD₅₀ was estimated by the method described by Litchfield & Wilcoxon [19]. The mice were assessed daily throughout the study to monitor their body weight variation, consumption of food and water.

Analysis of hematological and biochemical parameters

For the evaluation of hematological and biochemical parameters of blood was evaluated using the method described by Vasconcelos *et al* [20]. Blood was removed after 14 days through brachial plexus for laboratory analysis of hematological parameters: count of erythrocytes, hemoglobin, hematocrit, the mean corpuscular volume (MCV), the mean corpuscular hemoglobin (MCH), the mean corpuscular hemoglobin concentration (MCHC), leukocytes, lymphocytes and platelets. The biochemical parameters analyzed in serum samples were

triglycerides, AST/TGO, ALT/TGP, urea and creatinine. For the determination of hematological parameters, hematology analyser Sysmex XT-2000 was used. For the determination of biochemical parameters, an automatic analyser Wiener BT 3000 Plus was used.

Statistical analysis

The data obtained were analyzed using the GraphPad Prism® version 4.0 and expressed as mean \pm SEM. Statistically significant differences between groups were calculated by the application of analysis of variance (ANOVA) followed by Dunnett's test. Values were considered statistically significant at $p < 0.05$.

RESULTS

Phytochemical profile of extract

Phenolic profiles at 320 nm for the BI-EtOH evaluated are presented in Figure 1. The chromatogram shows the presence of nine peaks with different retention times: 11.79 (1), 14.44 (2), 15.14 (3), 15.57 (4), 16.67 (5), 17.62 (6), 18.09 (7), 19.01 (8) and 19.89 (9). Based on their UV-Vis spectral data and their retention time, the compounds have UV band characteristic for coumarin and flavonoid derivatives. These compounds are under investigation.

Anti-nociceptive activity of extract

BI-EtOH significantly reduced writhing induced by 0.9 % acetic acid. The significant protective effects were observed as 91.80, 93.44 and 78.68 % ($p < 0.01$) at 100, 200 and 400 mg/kg of the extract, respectively, while ASA (200 mg/kg) had 95.08 %. Morphine (10 mg/kg) abolished the nociceptive response (Figure 2).

Analgesic activity of extract

BI-EtOH had analgesic effects on both the first (0 - 5) and second phase (15 - 30) of formalin-induced pain. These phases correspond to neurogenic and inflammatory pains, respectively. BI-EtOH (100, 200 and 400 mg/kg, i.p.) decreased by 60.86, 62.84 and 66.79 %, respectively, the paw licking time in the first phase, as well as 91.93, 82.18 and 88.73 %, respectively, in the second phase of the formalin test (Figure 3). The treatment with acetylsalicylic acid and morphine was also able to inhibit the first and second phases. The pre-treatment with naloxone (1.5 mg/kg, i.p.) reversed the




Figure 1: High performance liquid chromatography profile of *Bromelia laciniosa* ethanol extract recorded at 320 nm





Figure 2: Antinociceptive activity of *B. laciniosa* (BI-EtOH 100, 200 and 400 mg/kg), acetylsalicylic acid (ASA 200 mg/kg) and morphine (10 mg/kg) on acetic acid induced writhing test. Values are mean \pm S.E.M. $**p < 0.01$, significantly different from control; ANOVA followed Dunnett's test (n = 6)






Figure 3: Effect of ethanol extract of *B. laciniosa* (BI-EtOH), acetylsalicylic acid (ASA), morphine, morphine + naloxone (Morph + NLX; 10 mg + 1.5 mg/kg) and BI-EtOH + NLX (100 mg + 1.5 mg/kg) on formalin test; values are mean \pm S.E.M.; * $p < 0.05$, ** $p < 0.01$, significantly different from control; ANOVA followed Dunnett's test ($n = 6$)

antinociceptive activity of the extract at dose of 100 mg/kg in the first phase of this test. The effect of morphine (10 mg/kg) was also reversed by naloxone.

Opioid antinociceptive activity

Figure 4 shows the results of the hot plate test. The reaction time parameter was only significantly increased at a dose of 100 mg/kg in 60 min. The effect of morphine was reversed by naloxone.

Acute toxicity

In the acute toxicity of BI-EtOH, behavioral and physiological alterations were not observed. No animals died from the 2.0 g/kg intraperitoneally

and 5.0 g/kg orally, respectively, indicating low toxicity of the extract. The administration of the extract did not cause any appreciable alterations in water and food intake in any of the groups. Moreover, body weight gain during the observation period among the treated animals with 5 g/kg v.o. was statistically different when comparable to control group (Figure 5).

Hematological and biochemical profiles

The administration of intraperitoneal and oral doses of BI-EtOH did not cause erythrocytes, hemoglobin, hematocrit, MCV, MCH, MCHC, leukocytes, lymphocytes and platelets level to change (Table 1).




Figure 4: Effect of ethanolic extract of *B. laciniosa* (BI-EtOH), morphine, morphine + naloxone (Morph + NLX; 10 mg + 1.5 mg/kg) and BI-EtOH + NLX (100 mg + 1.5 mg/kg) on hot plate test; values are mean \pm S.E.M.; * $p < 0.05$, ** $p < 0.01$, significantly different from control; ANOVA followed Dunnett's test ($n = 6$)




Figure 5: Body weight of animals treated with BI-EtOH for 14 days (n = 10)

Table 1: Hematological profiles of Swiss mice treated with 2.0 g/kg intraperitoneally and 5.0 g/kg orally of crude ethanol extract of *Bromelia laciniosa* after 14 days

Parameter	Group		
	Control	Extract, 2g/kg i.p.	Extract, 5g/kg oral
Erythrocytes ($10^6/\text{mm}^3$)	8.05 ± 0.49	8.43 ± 0.15	8.09 ± 0.09
Hemoglobin (g/dl)	13.40 ± 0.91	12.88 ± 0.68	13.06 ± 0.27
Hematocrit (%)	42.41 ± 2.48	43.33 ± 1.25	42.84 ± 0.40
MCV (μ^3)	52.60 ± 1.36	51.88 ± 0.45	52.86 ± 0.46
MCH (μg)	16.60 ± 0.22	16.43 ± 0.18	16.78 ± 0.15
MCHC (%)	31.69 ± 0.83	31.88 ± 0.34	32.06 ± 0.40
Leukocytes ($10^3/\text{mm}^3$)	6.25 ± 0.57	5.88 ± 0.41	6.97 ± 0.59
Lymphocytes (%)	88.93 ± 5.36	88.53 ± 1.08	88.55 ± 1.35
Platelets ($10^3/\text{mm}^3$)	883.70 ± 108.30	856.90 ± 71.14	911.30 ± 73.18

Values are mean ± SEM (n = 10); Student's t-test (p < 0.05)

Table 2: Serum biochemical profile of Swiss mice treated with 2.0 g/kg intraperitoneally and 5.0 g/kg orally of ethanol extract of *Bromelia laciniosa* for 14 days

Parameter	Group		
	Control	Extract, 2 g/kg i.p.	Extract, 5 g/kg oral
Triglycerides (mg/dl)	133.30 ± 5.57	111.17 ± 15.21	141.80 ± 14.14
AST/GOT (U/l)	123.10 ± 11.23	111.70 ± 25.05	116.70 ± 12.61
ALT/GPT (U/l)	75.29 ± 8.58	60.23 ± 8.08	66.30 ± 7.22
Urea (mg/dl)	66.44 ± 4.40	65.89 ± 6.16	67.56 ± 4.84
Creatinine (mg/dl)	0.36 ± 0.01	0.42 ± 0.11	0.26 ± 0.02**

Values are mean ± SEM (n = 10); **p < 0.01; Student's t-test (p < 0.05)

Likewise, the values of triglycerides, AST/GOT, ALT/GPT and urea (mg/dl) showed no significant changes. However, a significant decrease in the creatinine in the group treated with 5 g/kg by oral route was observed when compared to the control group (Table 2).

DISCUSSION

The present study shows that the ethanolic extract of *Bromelia laciniosa* has phenolic compounds, which are possibly responsible for their antinociceptive properties. A HPLC fingerprint of phenolic compounds was developed and showed the presence of characteristic peaks for these compounds.

The first test to evaluate the antinociceptive activity of BI-EtOH was the writhing induced by acetic acid. Acetic acid-induced writhing is a standard, simple, and sensitive test for measuring analgesia induced by both opioids and peripherally acting analgesics. Additionally, although this test is a nonspecific model, it is widely used for analgesic screening and involves local peritoneal receptors [21]. BI-EtOH significantly reduced the acetic acid-induced writhing in mice. These results support the hypothesis of BI-EtOH participation in the inhibition of prostaglandin synthesis, as the nociceptive mechanism involves the process or release of arachidonic acid metabolites via cyclooxygenase (COX), prostaglandin biosynthesis or other peripheral pathway [22]. A

positive result with this test is indicative of antinociceptive activity in the extract under investigation, which may be of central or peripheral origin.

In order to distinguish between the central and peripheral antinociceptive action, the formalin test was performed. Subcutaneous injection of formalin into the animal hind paw evokes an array of stereotyped behaviors. The nociceptive response to formalin occurs in a biphasic pattern; there is an initial acute period (phase 1) and, after a short period of remission, phase 2 begins and consists of a longer period of sustained activity. The phase 1 corresponds to acute nociceptive neurogenic pain, and is sensitive to analgesic drugs that interact with opioid system. The phase 2 corresponds to an inflammatory pain, dependent on several inflammatory mediators release and action, and the expression of nociceptive behavior in this phase is very sensitive to non-steroid anti-inflammatory drugs as the cyclooxygenase inhibitors. Drugs that act primarily as central analgesics inhibit both phases while peripherally acting drugs inhibit only the second phase [23]. The extract was able to block both phases of the formalin response although the effect was more pronounced in the second phase. The effect of extract on the first and second phases of formalin test suggests that its activity may be resulted from its central action when compared with morphine activity in this respect. The pre-treatment with naloxone reversed the antinociceptive activity of the extract in the first phase of this test. The results suggest a possible involvement of opioid receptors in the antinociceptive effect of the extract. In this study, acetylsalicylic acid and morphine was also able to inhibit both phases of the formalin test. Previous study showed that acetylsalicylic acid and paracetamol to have actions independent of their inhibition of prostaglandin synthesis and they also have effects on non-inflammatory pain [24], which was observed in this study for the AAS.

The evaluation of BI-EtOH on hot plate response showed that the extract increases the latency time only at dose of 100 mg/kg after 60 min. As the hot plate test is a specific central antinociceptive test, it is possible that BI-EtOH exert their antinociceptive effect at least in part through central mechanisms, as observed in the formalin test by inhibition of both phases of the test.

The use of medicinal plants has been very significant in several populations, especially in the Northeast of Brazil. However, the popular or traditional uses are not sufficient to validate the

herbal medicines as effective and safe. It is necessary to carry out toxicological studies to evaluate safety parameters which are not observed in the popular use of these plants [25].

The tests for acute toxicity of BI-EtOH did not demonstrate signs of lethality in mice at doses tested. A 2.0 and 5.0 g/kg body weight administered by via intraperitoneal and oral, respectively, dose were considered as the "limit test", as recommended by acute toxicity testing procedures [20]. In the acute toxicity of BI-EtOH, behavioral and physiological alterations were not observed and no animal died in the doses of 2.0 g/kg intraperitoneally and 5.0 g/kg orally, respectively, indicating low toxicity of the extract. In this experiment was observed that the BI-EtOH has $LD_{50} > 5000$ mg/kg. According to Kennedy *et al* [26] substances that present LD_{50} higher than 5.0 g/kg by oral route can be considered practically non-toxic.

There was no significant variation in hematological parameters in the groups treated with the extract compared to control. In regard to biochemical parameters a significant decrease in the creatinine in the group treated with 5 g/kg by oral route was observed when compared to the control group. Creatinine is a good indicator of kidney function. Alterations in their levels suggest alterations in this organ. Histopathological analysis of the kidneys revealed that the histological structure of renal tubules were preserved (data not shown).

CONCLUSION

The present work indicates that *Bromelia laciniosa* is a source of phenolic compounds and exhibit antinociceptive properties. Peripheral and, at least in part, central mechanisms may be involved in the antinociceptive effect. Further studies currently in progress will throw more light on the mechanisms of action underlying the effects observed in this investigation. The results obtained so far show that the plant is non-toxic at the doses used.

ACKNOWLEDGEMENT

This work was supported by grants from Brazilian agencies CNPq (Process 476770/2010-6) and FACEPE (Process APQ-0542-4.03/10).

REFERENCES

1. Chedier LM, Kaplan MAC. Chemical ecology of three species of Bromeliaceae. *Bromelia* 1996; 3: 25-31.

2. Luther HE. An alphabetical list of bromeliad binomials. Sarasota, The Bromeliad Society International, 2008.
3. Manetti LM, Delaporte RH, Laverde-Junior A. Metabólitos secundários da família Bromeliaceae. *Quim. Nova* 2009; 7: 1885-1897.
4. Delaporte RH, Sarragiotto MH, Takemura OS, Sanchez GM, Filho BPD, Nakamura CV. Evaluation of the antioedematogenic, free radical scavenging and antimicrobial activities of aerial parts of *Tillandsia streptocarpa* Baker – Bromeliaceae. *J. Ethnopharmacol.* 2004; 95: 229-233.
5. Amendoeira FC, Frutuoso VS, Chedier LM, Pearman AT, Figueiredo MR, Kaplan MAC, Prescott SM, Bozza PT, Castro-Faria-Neto HC. Antinociceptive effect of *Nidularium procerum*: a Bromeliaceae from the Brazilian coastal rain Forest. *Phytomedicine* 2005; 12: 78-87.
6. Vieira-de-Abreu A, Amendoeira FC, Gomes GS, Zanon C, Chedier LM, Figueiredo MR, Kaplan MA, Frutuoso VS, Castro-Faria-Neto HC, Weller PF, et al. Anti-allergic properties of the Bromeliaceae *Nidularium procerum*: Inhibition of eosinophil activation and influx. *Int Immunopharmacol.* 2005; 5: 1966-1974.
7. Carvalho KIM, Fernandes HB, Machado FDF, Oliveira IS, Oliveira FA, Nunes PHM, Lima JT, Almeida JRGS, Oliveira RCM. Antiulcer activity of ethanolic extract of *Encholirium spectabile* Mart. ex Schult & Schult f. (Bromeliaceae) in rodents. *Biol Res.* 2010; 43: 459-465.
8. Manetti LM, Turra AF, Takemura OS, Svidzinski TIE, Laverde-Junior A. Avaliação das atividades antimicrobiana, citotóxica, moluscicida e antioxidante de *Bromelia antiacantha* Bertol. (Bromeliaceae). *Rev. Bras. Pl. Med.* 2010; 12: 406-413.
9. Coelho RG, Honda NK, Vieira MC, Brum RL, Pavan FR, Leite CQF, Cardoso CAL. Chemical composition and antioxidant and antimycobacterial activities of *Bromelia balansae* (Bromeliaceae). *J Med Food* 2010; 13: 1277-1280.
10. Agra MF, Freitas PF, Barbosa-Filho JM. Synopsis of the plants known as medicinal and poisonous in Northeast of Brazil. *Braz. J. Pharmacogn.* 2007; 17: 114-140.
11. Santos VNC, Freitas RA, Deschamps FC, Biavatti, MW. Ripe fruits of *Bromelia antiacantha*: investigations on the chemical and bioactivity profile. *Braz. J. Pharmacogn.* 2009; 19: 358-365.
12. Dutra AS, Teófilo EM, Medeiros-Filho S. Germinação de sementes de macambira (*Bromelia laciniosa* Mart. ex Schult). *Revista Caatinga* 2010; 23: 12-17.
13. Angelim AES, Moraes JPS, Silva JAB, Gervásio, RCRG. Germinação e aspectos morfológicos de plantas de macambira (*Bromelia laciniosa*), encontradas na Região do Vale do São Francisco. *R. Bras. Bioci.* 2007; 5: 1065-1067.
14. Albuquerque UP, Medeiros PM, Almeida ALS, Monteiro JM, Lins-Neto EMF, Melo JG, Santos JP. Medicinal plants of the caatinga (semi-arid) vegetation of NE Brazil: a quantitative approach. *J Ethnopharmacol.* 2007; 114: 325-354.
15. Koster R, Anderson M, De Beer EJ. Acetic acid for analgesic screening. *Fed Proc.* 1959; 18: 412-416.
16. Queiroz AC, Lira DP, Dias TL, Souza ET, Matta CB, Aquino AB, Silva LH, Silva DJ, Mella EA, Agra MF, Barbosa-Filho JM, Araújo-Júnior JX, Santos BV, Alexandre-Moreira MS. The antinociceptive and anti-inflammatory activities of *Piptadenia stipulacea* Benth. (Fabaceae). *J. Ethnopharmacol.* 2010; 128: 377-383.
17. Oliveira RRB, Góis RMO, Siqueira RS, Almeida JRGS, Lima JT, Nunes XP, Oliveira VR, Siqueira JS, Quintans-Júnior LJ. Antinociceptive effect of the ethanolic extract of *Amburana cearensis* (Allemão) A.C. Sm., Fabaceae, in mice. *Braz J Pharmacogn.* 2009; 19: 672-676.
18. Almeida JRGS, Lima JT, Oliveira HR, Oliveira MR, Meira PRM, Lúcio ASSC, Barbosa-Filho JM, Quintans-Júnior LJ. Antinociceptive activity of discretamine isolated from *Duguetia moricandiana*. *Nat Prod Res.* 2011; 25: 1908-1915.
19. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. *J. Pharmacol. Exp. Ther.* 1949; 96: 99-113.
20. Vasconcelos THC, Modesto-Filho J, Diniz MFFM, Santos HB, Aguiar FB, Moreira PVL. Estudo toxicológico pré-clínico agudo com o extrato hidroalcoólico das folhas de *Cissus sicyoides* L (Vitaceae). *Braz J Pharmacogn* 2007; 17: 583-591.
21. Alexandre-Moreira MS, Piuvezam MR, Araújo CC, Thomas G. Studies on the anti-inflammatory and analgesic activity of *Curatella americana* L J *Ethnopharmacol.* 1999; 67: 171-177.
22. Guimarães AG, Melo MS, Bonfim RR, Passos LO, Machado SMF, Ribeiro AS, Sobral M, Thomazzi SM, Quintans-Júnior LJ. Antinociceptive and anti-inflammatory effects of the essential oil of *Eugenia candolleana* DC., Myrtaceae on mice. *Braz. J. Pharmacogn.* 2009; 19: 883-887.
23. Couto VM, Vilela FC, Dias DF, Santos MH, Soncini R, Nascimento CGO, Giusti-Paiva A. Antinociceptive effect of extract of *Emilia sonchifolia* in mice. *J Ethnopharmacol.* 2011; 134: 348-353.
24. Hunskaar S, Hole K. The formalin test in mice: dissociation between inflammatory and non-inflammatory pain. *Pain* 1987; 30: 103-114.
25. Almeida JRGS, Guimarães AL, Oliveira AP, Araújo ECC, Silva FS, Neves LF, Oliveira RA, Sá PG, Quintans-Júnior LJ: Evaluation of hypoglycemic potential and pre-clinical toxicology of *Morus nigra* L. (Moraceae). *Lat. Am. J. Pharm.* 2011; 30: 96-100.
26. Kennedy GL, Ferenz RL, Burgess BA. Estimation of acute oral toxicity in rats by determination of the approximate lethal dose rather than the LD50. *J. Appl. Toxicol.* 1986; 6: 145-148.